SI2852389T1 - Sestavki, obsegajoči kratkotrajno-delujoče benzodiazepine - Google Patents
Sestavki, obsegajoči kratkotrajno-delujoče benzodiazepine Download PDFInfo
- Publication number
- SI2852389T1 SI2852389T1 SI201330840T SI201330840T SI2852389T1 SI 2852389 T1 SI2852389 T1 SI 2852389T1 SI 201330840 T SI201330840 T SI 201330840T SI 201330840 T SI201330840 T SI 201330840T SI 2852389 T1 SI2852389 T1 SI 2852389T1
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- dextran
- benzodiazepine
- pharmaceutically acceptable
- hygroscopic excipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (12)
- SESTAVKI, OBSEGAJOČI KRATKOTRAJNO-DELUJOČE BENZODIAZEPINE EP2852389 Patentni zahtevki1. Liofiliziran ali pršno-posušen sestavek, obsegajoč vsaj en benzodiazepin po formuli (I)z Wje H; X je CH2; n je 1; Yje CH2; m je 1; Z je O; R1 je CH3, CH2CH3, CH2CH2CH3, CH(CH3)2 ali CH2CH(CH3)2; R2 je 2-fluorofenil, 2-klorofenil ali 2-piridil; R3 je Cl ali Br; R4, R5 in R8 tvorijo skupino-CR8=U-V= pri čemer je R8 vodik, C1-4 alkil ali C1-3 hidroksialkil, U je N ali CR9 pri čemer je R9 H, C1-4 alkil, C1-3 hidroksialkil ali C1-4 alkoksi, V je N ali CH in je p nič ali njega farmacevtsko sprejemljiva sol, pri čemer sestavek obsega vsaj en farmacevtsko sprejemljiv higroskopski ekscipient, pri čemer je higroskopski ekscipient ogljikov hidrat, izbran izmed skupine, ki jo sestavljajo disaharidi in dekstran, in je opcijsko sestavek vsaj delno amorfen.
- 2. Sestavek po zahtevku 1, pri čemer je benzodiazepin po formuli (I) metil 3-[(4S)-8-bromo-1 -metil-6-(piridin-2-il)-4H-imidazo[1,2-a][1,4]benzadiazepin-4-iljprapanoat (remimazolam).
- 3. Sestavek po zahtevku 2, pri čemer je v farmacevtsko sprejemljivi soli benzodiazepin formuliran v kationski obliki in je nasprotni ion benzen sulfonat (besilat).
- 4. Sestavek po kateremkoli od zahtevkov 1 do 3, pri čemer ima dekstran molekulsko maso manj kot 150 kD.
- 5. Sestavek po kateremkoli od zahtevkov 1 do 3, pri čemer je disaharid izbran izmed skupine, ki jo sestavljajo laktoza, maltoza, saharoza in trehaloza.
- 6. Sestavek po kateremkoli od zahtevkov 1 do 3, pri čemer sestavek obsega zmes prvega higroskopskega ekscipienta in drugega higroskopskega ekscipienta.
- 7. Sestavek po zahtevku 6, pri čemer sestavek obsega zmes disaharida in dekstrana, prednostno zmesi laktoze in dekstrana.
- 8. Sestavek po zahtevku 7, pri čemer je utežno % razmerje med laktozo in dekstranom od 1: 1,0 do 1:10, prednostno od 1: 1,2 do 1: 5 in bolj prednostno 1: 1,5 ali 1:4.
- 9. Sestavek po kateremkoli od zahtevkov 1 do 3, pri čemer je utežno % razmerje med celotno količino higroskopskih ekscipientov in celotno količino benzodiazepinov ali njih soli, izračunano za bazo, v sestavku, od 20:1 do 1 : 1, prednostno od 12: 1 do 3: 1, najbolj prednostno od 9: 1 do 3: 1.
- 10. Sestavek po kateremkoli od zahtevkov 1 do 3, ki je farmacevtska formulacija.
- 11. Uporaba zmesi vsaj enega disaharida in vsaj enega dekstrana za pripravo liofiliziranega ali pršno posušenega farmacevtskega sestavka, ki obsega benzodiazepin z ester karboksilne kisline delom po zahtevku 1 ali njega farmacevtsko sprejemljivo sol, zlasti remimazolam.
- 12. Postopek za pripravo farmacevtskega sestavka, ki obsega korake a) dobava raztopine, ki obsega benzodiazepin po zahtevku 1 ali njega farmacevtsko sprejemljivo sol, zlasti remimazolam; b) dodajanje vsaj enega higroskopskega ekscipienta, ki je ogljikov hidrat, izbran izmed skupine, ki jo sestavljajo disaharidi in dekstran ali njih zmes z vsaj še enim higroskopskim ekscipientom; c) sušenje raztopine iz koraka b) z liofilizacijo ali pršnim sušenjem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168968 | 2012-05-22 | ||
| EP13730128.9A EP2852389B1 (en) | 2012-05-22 | 2013-05-22 | Compositions comprising short-acting benzodiazepines |
| PCT/EP2013/060543 WO2013174883A1 (en) | 2012-05-22 | 2013-05-22 | Compositions comprising short-acting benzodiazepines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2852389T1 true SI2852389T1 (sl) | 2018-02-28 |
Family
ID=48669863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201330840T SI2852389T1 (sl) | 2012-05-22 | 2013-05-22 | Sestavki, obsegajoči kratkotrajno-delujoče benzodiazepine |
Country Status (42)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007009128D1 (de) | 2006-07-10 | 2010-10-21 | Paion Uk Ltd | Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon |
| EP2305647A1 (en) | 2009-09-18 | 2011-04-06 | PAION UK Limited | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process |
| EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
| WO2015076340A1 (ja) * | 2013-11-21 | 2015-05-28 | 小野薬品工業株式会社 | 全身麻酔および／または鎮静のための注射用組成物 |
| WO2015119510A1 (en) | 2014-02-10 | 2015-08-13 | Biolumic Limited | Improvements in and relating to controlling characteristics of photosynthetic organisms |
| ES2807220T3 (es) | 2014-03-14 | 2021-02-22 | Biolumic Ltd | Método para mejorar el rendimiento y/o la resistencia al estrés de los cultivos |
| WO2016011943A1 (zh) * | 2014-07-23 | 2016-01-28 | 李勤耕 | 新的苯并二氮杂䓬类衍生物及其用途 |
| EP4091440A1 (en) | 2014-09-17 | 2022-11-23 | Biolumic Limited | Method of seed treatments and resulting products |
| CN105726495B (zh) * | 2014-12-12 | 2019-03-29 | 宜昌人福药业有限责任公司 | 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法 |
| CN107198691A (zh) * | 2016-03-17 | 2017-09-26 | 江苏恒瑞医药股份有限公司 | 一种瑞马唑仑的药物组合物 |
| BR112018071082A2 (pt) * | 2016-04-14 | 2019-02-05 | Paion Uk Ltd | benzodiazepinas nasais e inaladas oralmente |
| CN108289897B (zh) * | 2016-05-20 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 一种瑞马唑仑的药物组合物 |
| CA3034739A1 (en) | 2016-08-22 | 2018-03-01 | Biolumic Limited | System, device and methods of seed treatment |
| CN108503644B (zh) | 2016-12-09 | 2019-06-14 | 成都倍特药业有限公司 | 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途 |
| EP3714884A1 (en) | 2019-03-27 | 2020-09-30 | Paion UK Limited | Medical uses for benzodiazepines with a particular eeg pattern |
| CN112209932B (zh) * | 2019-07-12 | 2023-03-24 | 成都倍特药业股份有限公司 | 一种化合物氢溴酸盐的新固体形态及其制备方法和用途 |
| ES2803099B2 (es) | 2019-07-22 | 2021-11-08 | Moehs Iberica Sl | Procedimiento de obtención de besilato de remimazolam amorfo |
| CN114478535B (zh) * | 2020-10-23 | 2024-02-09 | 成都苑东生物制药股份有限公司 | 一种苯磺酸瑞马唑仑ii晶型的制备方法 |
| CN112462015B (zh) * | 2020-11-18 | 2022-07-12 | 海南倍特药业有限公司 | 一种氢溴酸瑞马唑仑细菌内毒素的检测方法 |
| CN114624351B (zh) * | 2020-12-14 | 2024-04-09 | 宜昌人福药业有限责任公司 | 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3520877A (en) * | 1967-10-02 | 1970-07-21 | Hoffmann La Roche | 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines |
| CA2143246C (en) | 1994-03-16 | 2000-08-22 | Thierry Godel | Imidazodiazepines |
| JP3001979B2 (ja) | 1995-01-06 | 2000-01-24 | エフ・ホフマン−ラ ロシュ アーゲー | ヒドロキシメチル−イミダゾジアゼピン類及びそれらのエステル |
| WO1996023790A1 (de) | 1995-02-02 | 1996-08-08 | F. Hoffmann-La Roche Ag | Acetylimidazobenzodiazepine |
| JPH0971533A (ja) * | 1995-06-30 | 1997-03-18 | Takeda Chem Ind Ltd | 凍結乾燥製剤 |
| US7160880B1 (en) * | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
| GB9911152D0 (en) | 1999-05-14 | 1999-07-14 | Glaxo Group Ltd | Short-acting benzodiazepines |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| EP1161949A1 (en) * | 2000-06-09 | 2001-12-12 | Warner-Lambert Company | Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease |
| BRPI0608087A2 (pt) * | 2005-02-15 | 2009-11-10 | Elan Pharma Int Ltd | formulações injetáveis e em aerossol de benzodiazepina em nanopartìculas |
| DE602007009128D1 (de) * | 2006-07-10 | 2010-10-21 | Paion Uk Ltd | Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon |
| GB0613692D0 (en) * | 2006-07-10 | 2006-08-16 | Cenes Ltd | Benzodiazepine salts |
| GB0613693D0 (en) * | 2006-07-10 | 2006-08-16 | Cenes Ltd | Benzodiazepine salts (3) |
| CN101352422B (zh) * | 2008-09-17 | 2011-04-20 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
| KR20120097508A (ko) * | 2009-11-05 | 2012-09-04 | 글락소스미스클라인 엘엘씨 | 벤조디아제핀 브로모도메인 억제제 |
| EP2450039A1 (en) * | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| CN102964349A (zh) * | 2011-08-31 | 2013-03-13 | 江苏恒瑞医药股份有限公司 | 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途 |
-
2013
- 2013-05-22 SI SI201330840T patent/SI2852389T1/sl unknown
- 2013-05-22 WO PCT/EP2013/060543 patent/WO2013174883A1/en active Application Filing
- 2013-05-22 SG SG11201407710VA patent/SG11201407710VA/en unknown
- 2013-05-22 TW TW102118175A patent/TWI590826B/zh active
- 2013-05-22 MX MX2014014225A patent/MX368854B/es active IP Right Grant
- 2013-05-22 GE GEAP201313666A patent/GEP20186852B/en unknown
- 2013-05-22 RS RS20171260A patent/RS56660B1/sr unknown
- 2013-05-22 CA CA2874247A patent/CA2874247C/en active Active
- 2013-05-22 AP AP2014008084A patent/AP2014008084A0/xx unknown
- 2013-05-22 AU AU2013265295A patent/AU2013265295B2/en active Active
- 2013-05-22 MY MYPI2014003222A patent/MY185117A/en unknown
- 2013-05-22 EA EA201492160A patent/EA032119B1/ru unknown
- 2013-05-22 BR BR112014029108-0A patent/BR112014029108B1/pt active IP Right Grant
- 2013-05-22 PT PT137301289T patent/PT2852389T/pt unknown
- 2013-05-22 JP JP2015513164A patent/JP6313286B2/ja active Active
- 2013-05-22 NZ NZ702063A patent/NZ702063A/en unknown
- 2013-05-22 KR KR1020147036021A patent/KR102116737B1/ko active Protection Beyond IP Right Term
- 2013-05-22 NO NO13730128A patent/NO2852389T3/no unknown
- 2013-05-22 ES ES13730128.9T patent/ES2651389T3/es active Active
- 2013-05-22 PL PL13730128T patent/PL2852389T4/pl unknown
- 2013-05-22 HU HUE13730128A patent/HUE037734T2/hu unknown
- 2013-05-22 PE PE2014002207A patent/PE20150683A1/es active IP Right Grant
- 2013-05-22 AR ARP130101779A patent/AR092008A1/es not_active Application Discontinuation
- 2013-05-22 MA MA37581A patent/MA37581B1/fr unknown
- 2013-05-22 US US14/402,590 patent/US20150148338A1/en not_active Abandoned
- 2013-05-22 UA UAA201413655A patent/UA115063C2/uk unknown
- 2013-05-22 DK DK13730128.9T patent/DK2852389T3/en active
- 2013-05-22 LT LTEP13730128.9T patent/LT2852389T/lt unknown
- 2013-05-22 EP EP13730128.9A patent/EP2852389B1/en active Active
- 2013-05-22 CN CN201380036582.2A patent/CN104968348B/zh active Active
- 2013-05-22 CN CN201810206738.1A patent/CN108578413A/zh active Pending
-
2014
- 2014-11-18 TN TN2014000479A patent/TN2014000479A1/fr unknown
- 2014-11-18 ZA ZA2014/08412A patent/ZA201408412B/en unknown
- 2014-11-19 IL IL235789A patent/IL235789B/en active IP Right Grant
- 2014-11-21 CL CL2014003171A patent/CL2014003171A1/es unknown
- 2014-11-21 PH PH12014502608A patent/PH12014502608B1/en unknown
- 2014-11-24 CO CO14258220A patent/CO7151503A2/es unknown
- 2014-12-19 EC ECIEPI201432553A patent/ECSP14032553A/es unknown
-
2015
- 2015-09-09 HK HK15108782.8A patent/HK1208164A1/xx unknown
-
2017
- 2017-12-04 HR HRP20171872TT patent/HRP20171872T1/hr unknown
-
2021
- 2021-08-16 US US17/402,730 patent/US20220040198A1/en active Pending
- 2021-09-17 LT LTPA2021521C patent/LTPA2021521I1/lt unknown
- 2021-09-20 HU HUS2100040C patent/HUS2100040I1/hu unknown
- 2021-09-20 LU LU00230C patent/LUC00230I2/fr unknown
- 2021-09-20 NO NO2021041C patent/NO2021041I1/no unknown
- 2021-09-20 FR FR21C1043C patent/FR21C1043I2/fr active Active
- 2021-09-21 NL NL301130C patent/NL301130I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2852389T1 (sl) | Sestavki, obsegajoči kratkotrajno-delujoče benzodiazepine | |
| JP2015517552A5 (sl) | ||
| AR032335A1 (es) | Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos | |
| ES2620612T3 (es) | Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo | |
| HRP20192159T1 (hr) | Spojevi za liječenje mišićne atrofije kralježnice | |
| CY1119813T1 (el) | Αλατα 2-φθορο-ν-μεθυλ-4-[7-(κινολιν-6-υλ-μεθυλ)-ιμιδαζο[1,2-β][1,2,4]τριαζιν-2-υλ]βενζαμιδιου και διαδικασιες που σχετιζονται με την παρασκευη αυτων | |
| HRP20171150T1 (hr) | Novi spojevi | |
| KR20170103838A (ko) | 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제 | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| JP2019531280A (ja) | エンドソームＴｏｌｌ様受容体の阻害剤としての化合物および組成物 | |
| HRP20170090T1 (hr) | Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze | |
| BR112014006840A2 (pt) | derivados de pirrolopirimidina e purina | |
| YU53298A (en) | Aryl pyrimidine derivatives | |
| MEP36508A (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| EA201170771A1 (ru) | Органические соединения | |
| MA35024B1 (fr) | Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine | |
| BRPI0809998B8 (pt) | composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas | |
| BR112013014184A2 (pt) | compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso | |
| BR0110240A (pt) | Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| AR015595A1 (es) | Compuestos derivados de pirazolo [4,3-d]-pirimidin-7-onas, composiciones farmaceuticas, formulacion veterinaria, uso de dichos compuestos en la preparacionde composicion y formulaciones. procedimientos para su uso, compuestos intermediarios, proceso para la preparacion de los compuestos. | |
| NZ598907A (en) | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | |
| CL2011000880A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer. | |
| SI2041133T1 (sl) | Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki | |
| EA201170770A1 (ru) | Органические соединения | |
| EA200600973A1 (ru) | ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2 |